Natera Inc

Stock Chart, Company Information, and Scan Results

$222.10(as of Jun 4, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Natera Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$222.10
Ticker SymbolNTRA
ExchangeNasdaq
SectorHealthcare
IndustryDiagnostics & Research
Employees6,135
CountyUSA
Market Cap$31,062.0M
EBIDTA-267.6M
10-Day Moving Average211.37
P/E Ratio-138.87
20-Day Moving Average205.16
Forward P/E Ratio0.00
50-Day Moving Average203.97
Earnings per Share-1.61
200-Day Moving Average203.83
Profit Margin-12.21%
RSI59.69
Shares Outstanding143.2M
ATR10.79
52-Week High256.36
Volume1,265,440
52-Week Low131.81
Most Recent Support Level204.16
Book Value1,774.0M
Most Recent Resistance Level225.70
P/B Ratio17.72
Upper Keltner229.44
P/S Ratio12.57
Lower Keltner180.88
Debt-to-Equity Ratio229.44
Next Earnings Date08/05/2026
Cash Surplus529.7M
Next Ex-Dividend DateUnknown

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in Januar

Natera Inc In Our Stock Scanner

As of Jun 05, 2026
As of ---
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.